|Bid||0.046 x 0|
|Ask||0.047 x 0|
|Day's Range||0.046 - 0.046|
|52 Week Range||0.042 - 0.078|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 4, 2016 - Mar 5, 2016|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||0.75|
Prana Biotechnology Ltd is pleased to announce it has received ethics committee approval and has commenced recruitment for its Phase I Clinical trial evaluating the safety, tolerability and pharmacokinetics of the Company’s lead drug candidate, PBT434, in healthy volunteers.
NEW YORK, NY / ACCESSWIRE / October 20, 2017 / The Dow Jones and S&P 500 rallied late to close in the green Thursday, which was the 30th anniversary of the 1987 Black Monday stock market crash. The Dow ...
Prana Biotechnology Ltd today announced a research collaboration with Takeda Pharmaceuticals International, Inc. to study the ability of Prana’s investigational movement disorders compound, PBT434, to slow or prevent neurodegeneration of the gastrointestinal system.
Prana Biotechnology Ltd today announced the article “The novel compound PBT434 prevents iron-mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson’s disease” was accepted for publication in the peer reviewed journal Acta Neuropathologica Communications.
NEW YORK, NY / ACCESSWIRE / July 5, 2017 / Shares of both Opexa Therapeutics and Prana Biotechnology saw a big trading day on Monday. Opexa shares exploded after traders found out that the company would ...